Endpoint
Mini-Mental State Examination total score
CAT:outcome/mmse-total-scorereported in points (0-30)3 findings from 3 compounds
What moved it
How to read these marks3 findings · 3 compounds · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| choline | up | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| resveratrol | up | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| melatonin | up | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
Reported to move it
3 findings
resveratrol — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Compared with CG after treatment, EG obtained obviously higher MMSE score (P < 0.001) and significantly lower ADAS-cog score (P < 0.001) (see Figure 1).”
Quoted verbatim from Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer's Disease.. - Study
- RCT
- Participants
- 90
- Duration
- 2 months
- Dose
- 1-2 RES tablets (1.0 g each) daily as a dietary supplement, added to donepezil hydrochloride
- Population
- patients with Alzheimer's disease, all also receiving donepezil hydrochloride as background therapy in both arms (EG: donepezil + resveratrol; CG: donepezil alone), 2-month treatment
Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer's Disease.2022PMID:35368930Permalink
choline — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The pooled effect estimate showed that patients who received α-GPC and donepezil had significantly improved cognitive function than those who received donepezil and placebo as measured by MMSE (4 RCTs, MD: 1.72, 95% CI: 0.20 to 3.25, I2 = 61%, Fig. 3).”
Quoted verbatim from Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- choline alphoscerate (alpha-GPC) 1200 mg/day plus donepezil 10 mg/day versus placebo plus donepezil 10 mg/day
- Population
- Adults aged 50 years and older with neurological disorders and cognitive impairment (pooled RCTs); donepezil 10 mg/day given in both arms as background
Effect 1.72 mean difference, 95% CI 0.2 to 3.25
Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.2023PMID:36683513Permalink
melatonin — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“AD patients receiving >12 weeks of melatonin treatment improved mini-mental state examination (MMSE) score [MD: 1.82 (1.01; 2.63) p < 0.0001].”
Quoted verbatim from Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer's disease and insomnia: A systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Alzheimer's disease patients receiving more than 12 weeks of melatonin treatment (meta-analysis of RCTs)
Effect 1.82 mean difference, 95% CI 1.01 to 2.63
Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer's disease and insomnia: A systematic review and meta-analysis of randomized controlled trials.2021PMID:33957167Permalink
How it is measured
Global cognitive screening score on the Mini-Mental State Examination, 0 to 30, administered by a trained assessor. Where a study reports a modified or telephone version, that is recorded with each finding, since the ceiling and the item set differ.
Sources cited
3 papers
- Subject
- mini-mental state examination total score
- Findings
- 3
- Papers
- 3
Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.record2023PMID:366835131 finding
Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer's Disease.record2022PMID:353689301 finding
Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer's disease and insomnia: A systematic review and meta-analysis of randomized controlled trials.record2021PMID:339571671 finding